TADA2B

Across TCGA pan-cancer cohorts, TADA2B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TADA2B data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher TADA2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TADA2B expression acts as an unfavorable survival marker.

DLBC, SKCM, and PCPG are the cancer types where TADA2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
SKCM	DFS	Median	All	0.131	0.761	<.001	17	view →
PCPG	OS	Median	All	0.078	0.955	<.001	12	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	12	view →
COAD	OS	Median	All	0.001	0.871	<.001	12	view →
PRAD	DFS	Median	All	0.617	0.886	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TADA2B–DLBC (OS)

Open the DLBC breakdown →